We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+2.26%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
-$221M
Cap. Flow
-$84.5M
Cap. Flow %
-3.86%
Top 10 Hldgs %
70.17%
Holding
54
New
4
Increased
10
Reduced
8
Closed
7

Top Buys

1
MAZE
Maze Therapeutics
MAZE
+$49.7M
2
DYN icon
Dyne Therapeutics
DYN
+$20.6M
3
RNAM
Avidity Biosciences
RNAM
+$16.4M
4
ZLAB icon
Zai Lab
ZLAB
+$10.8M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$10.6M

Top Sells

1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$66.1M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$33.9M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$21.7M
4
ANAB icon
AnaptysBio
ANAB
+$20.8M
5
KRYS icon
Krystal Biotech
KRYS
+$16.8M

Sector Composition

1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
26
Mereo BioPharma
MREO
$50.7M
$17.6M 0.8%
7,819,863
+2,722,084
+53% +$7.7M
MRUS
27
DELISTED
Merus
MRUS
$15.7M 0.72%
373,100
– –
RNAM
28
DELISTED
Avidity Biosciences
RNAM
$15.5M 0.71%
+525,000
New +$16.4M
HLVX
29
DELISTED
HilleVax
HLVX
$15.4M 0.7%
10,617,062
– –
DYN icon
30
Dyne Therapeutics
DYN
$3.84B
$15.1M 0.69%
+1,443,341
New +$20.6M
ZLAB icon
31
Zai Lab
ZLAB
$2.26B
$12.6M 0.58%
+350,000
New +$10.8M
IMCR icon
32
Immunocore
IMCR
$1.79B
$8.94M 0.41%
301,170
+192,408
+177% +$5.77M
ORIC icon
33
Oric Pharmaceuticals
ORIC
$1.09B
$7.87M 0.36%
1,410,193
-2,478,045
-64% -$21.7M
ACAD icon
34
Acadia Pharmaceuticals
ACAD
$4.34B
$7.81M 0.36%
470,338
– –
DSGN icon
35
Design Therapeutics
DSGN
$794M
$7.54M 0.34%
1,953,547
– –
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$366M
$7.2M 0.33%
1,079,025
-400,000
-27% -$3.95M
AUTL
37
Autolus Therapeutics
AUTL
$383M
$7.17M 0.33%
4,623,324
– –
ORKA
38
Oruka Therapeutics
ORKA
$5.42B
$5.98M 0.27%
583,327
– –
ALLO icon
39
Allogene Therapeutics
ALLO
$618M
$5.65M 0.26%
3,868,750
+1,001,000
+35% +$1.89M
IMTX icon
40
Immatics
IMTX
$1.32B
$5.63M 0.26%
1,247,911
-900,000
-42% -$4.7M
COGT icon
41
Cogent Biosciences
COGT
$6.64B
$5.61M 0.26%
936,576
– –
ADVM
42
DELISTED
Adverum Biotechnologies
ADVM
$4.67M 0.21%
1,069,244
– –
NAMSW icon
43
NewAmsterdam Pharma Warrant
NAMSW
$4.5M 0.21%
500,333
– –
MGNX icon
44
MacroGenics
MGNX
$270M
$4.03M 0.18%
3,175,665
– –
LXEO icon
45
Lexeo Therapeutics
LXEO
$361M
$3.32M 0.15%
955,515
– –
SLN
46
Silence Therapeutics
SLN
$518M
$3.24M 0.15%
1,148,591
– –
ELEV
47
DELISTED
Elevation Oncology
ELEV
$1.55M 0.07%
5,993,579
– –
ANAB icon
48
AnaptysBio
ANAB
$1.68B
– –
-1,573,719
Closed -$20.8M
ARVN icon
49
Arvinas
ARVN
$521M
– –
-285,331
Closed -$5.47M
DAWN
50
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-689,655
Closed -$8.74M
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2025 Portfolio in Review

As of Q1 2025, Frazier Life Sciences Management held 54 positions worth $2.19B, down 9.2% from $2.41B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Frazier Life Sciences Management withdrew a net $84.5M in Q1 2025, closing 7 positions and reducing 8 holdings. Its most notable exit was Edgewise Therapeutics, an estimated $33.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Frazier Life Sciences Management opened a new position in Maze Therapeutics worth $45.5M.

  • Frazier Life Sciences Management's largest Q1 2025 buy was Maze Therapeutics: 4,129,001 shares worth $45.5M.
  • Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2025, an estimated $10.6M increase.
  • Frazier Life Sciences Management's biggest Q1 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $66.1M.
  • Frazier Life Sciences Management fully exited Edgewise Therapeutics in Q1 2025, selling an estimated $33.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 70% of its $2.19B portfolio in Q1 2025.
  • Frazier Life Sciences Management opened 4 new positions and closed 7 in Q1 2025.
  • Frazier Life Sciences Management's portfolio value fell 9.2% quarter-over-quarter to $2.19B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.